Alcon Completes LumiThera Acquisition to Expand Dry AMD Portfolio

Alcon has officially completed its acquisition of LumiThera, the company behind the Valeda® Photobiomodulation (PBM) system, a noninvasive treatment for early and intermediate dry age-related macular degeneration (AMD). This acquisition marks Alcon’s entry into the retina clinic space, complementing its existing strength in vitreoretinal surgery.

Originally announced in July 2025, the acquisition supports Alcon’s strategy to diversify its retina portfolio. Financial details of the transaction were not disclosed.

About the Valeda PBM System

The Valeda PBM system is described by Alcon as the first and only approved device utilizing non-phototoxic light therapy for treating early and intermediate dry AMD, as well as non-central geographic atrophy, a subset of late-stage dry AMD.

The technology uses three specific light wavelengths to enhance mitochondrial function and promote cellular health in the retina. The treatment is noninvasive and designed for office-based use.

Clinical Evidence and Patient Outcomes

Results from the LIGHTSITE I, II, and III clinical trials demonstrated notable outcomes:

       • Improved visual acuity and contrast sensitivity

       • Average gain of one line in ETDRS visual acuity over two years of treatment

       • 97% of patients reported no treatment-related discomfort

These findings support Valeda’s role as an early intervention tool in dry AMD management.

Commenting on the acquisition, Ian Bell, SVP and Chief Operating Officer at Alcon, stated:

“Since Alcon entered the retina space in 1997, we’ve focused our efforts mainly in surgical, delivering leading products and solutions for the operating room. As we welcome LumiThera and Valeda PBM to Alcon, we move into the retina clinic and the dry AMD space. We look forward to broadening access and availability to Valeda PBM so more dry AMD patients can benefit from early intervention.”

Market Availability and Future Plans

Valeda PBM is currently available in the United States, as well as select European and Latin American markets. Alcon announced plans to expand access to the treatment in these regions and is preparing for additional regulatory submissions and global expansion, beginning in 2026.